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ABSTRACT
Ultraviolet radiation (UVR) is known to suppress im-
mune responses in human subjects. The purpose of this
study was to develop dose responses across a broad range
of skin pigmentation in order to facilitate risk assess-
ment. UVR was administered using FS 20 bulbs. Skin
pigmentation and UVR sensitivity were evaluated using
Fitzpatrick classifications, minimal erythemal dose
(MED), slope of the erythemal dose response curve
(sED), baseline pigmentation and tanning response. To
assess immune responses dinitrochlorobenzene (DNCB)
was applied to irradiated buttock skin 72 h after irradi-
ation. Two weeks later DNCB was applied to the inside
upper arm. Skin thickness was measured before and af-
ter challenge. Dose response was modeled (to obtain a
regression line) for the entire group of 185 subjects. With
the exception of sED none of the above-mentioned pig-
mentation indicators contributed significantly to vari-
ability around the regression line. Thus, differences in
sensitivity for multiple skin types based on Fitzpatrick
classification or MED were not observed. However, dif-
ferences in immune sensitivity to UVR were detected be-
tween subjects with steep erythemal dose response curves
and those with moderate or flat responses. For subjects
with steep erythemal responses the dose calculated to
suppress the immune response by 50% was 114 mJ/cm2.
This group included individuals with Fitzpatrick skin
types I–V, MED for these subjects ranged from 30 to 80
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mJ/cm2. The 50% suppression dose for subjects with
weak or no erythemal response could not be computed
(the dose response was flat). This resistant group includ-
ed subjects with skin types IV–VI and MED for these
subjects ranged from 41 to .105 mJ/cm2. This study pro-
vides a human dose response for UVR suppression of
contact sensitivity that will be useful in risk assessment.
It is the first study to provide this information using the
FS sun lamp and is the first study to include people of
color. The sED appears to be a new variable for identi-
fying sensitive subjects at risk of UVR-induced immune
suppression.
INTRODUCTION
The immunosuppressive effects of ultraviolet radiation
(UVR)‡ were originally described in mice with respect to
immune responses to UV-induced skin cancers (1,2). Sub-
sequently, UVR-induced suppression of responses to contact
sensitizers (3,4) and a variety of infectious agents were ob-
served (5–9). Immunosuppression has now been demonstrat-
ed in both light- and dark-skinned human subjects (10–12).
Recently, the dose response for UVR-induced suppression
of contact hypersensitivity in human subjects exposed via a
solar simulator was reported (13). However, this study was
limited to Caucasian subjects. A dose response for people
of color has not been previously determined. Dose response
data are necessary in order to assess the risk of immunosup-
pression associated with increased UVR exposures projected
to occur as a result of stratospheric ozone depletion (14).
Determining the relative sensitivity of population subsets
based on the degree of skin pigmentation is important in
defining the population at risk and also has implications on
the types of adverse health effects (diseases) of concern. Fol-
lowing UV exposure the capacity to mount a primary im-
‡Abbreviations: CHS, contact hypersensitivity; DNCB, dinitrochlo-
robenzene; DPCP diphenylcyclopropenone; MED, minimal ery-
themal dose; MSLR, mixed skin lymphocyte response; sED, slope
of the erythemal dose response curve; SSR, solar simulated ra-
diation; UVB, ultraviolet radiation B; UVR, ultraviolet radiation.
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Table 1. Spectral distribution of UV wavebands present in FS-20
source*
















*Output measurement at 2 nm intervals were normalized at their
peak values; percent of UV for each wave band between 250
and 400 nm is shown.
mune response is transiently impaired (for about 2 weeks in
mice) (15,16); adverse health effects may occur during this
period as a result of primary challenges to the skin immune
system. In lightly pigmented individuals these challenges in-
clude recognition of early skin cancer transformed or initi-
ated cells (17). The incidence of nonmelanoma skin cancer
among darkly pigmented individuals is very low (18), pre-
sumably because pigmentation protects against tumor initi-
ation (12). However, viral (e.g. Herpes viruses), fungal (e.g.
Candida albicans), bacterial (e.g. Mycobacteria, Borrelia)
and parasitic infections (e.g. Leishmania) also challenge the
skin immune system. The resulting diseases could be en-
hanced in individuals exposed to UVR and may be of con-
cern to both darkly pigmented and fair-skinned individuals
depending on the effect that pigmentation has on the sus-
ceptibility to UVR-induced immune suppression. Similarly,
UVR-induced immune suppression may impair the effec-
tiveness of vaccines that are delivered via the skin and de-
pend on the successful activation of T cell–mediated re-
sponses.
In this study we assessed the immune response to contact
sensitizers, a sensitive and highly quantitative assay, in hu-
man subjects of different skin types with and without ex-
posure to UVR. The purpose was to determine the relation-
ship between ultraviolet radiation B (UVB) dose and degree
of immune suppression in human subjects across a broad
range of skin pigmentation. The UVB response was empha-
sized because risk assessment in this area centers on pro-
jected health impacts of increased UVB penetration to the
earth’s surface as a result of decreased stratospheric ozone.
METHODS
UVR dosimetry and exposure. To administer UVR a portable pho-
totherapy device was utilized (Derma control, Frankfort, IL) con-
taining six FS20 bulbs which emitted light at 0.25 mW/cm2 at a 10
in. source-to-skin distance. The spectral distribution of the UV
wavebands present in this source is shown in Table 1. An interna-
tional light IL443 Phototherapy Radiometer w/SEE 1240 Detector/
UVB filter was used to measure the UVB irradiance and data are
reported as the readout of this device in mJ/cm2. The source was
chosen to facilitate direct comparisons between effects in humans
and mice (a very large database using this same light source is avail-
able for mice). Also, much of the spectral distribution for this source
is in the range likely to be affected by the depletion of the strato-
spheric ozone.
Subject selection and determination of skin type. The protocol,
advertisement and informed consent form were approved by the Uni-
versity of Michigan Institutional Review Board. Subjects were re-
cruited between the ages of 18 and 62 years. Individuals who were
pregnant or nursing, were on medication or had a history of chronic
disease or recent significant sun or tanning booth exposure were
excluded from the study.
Several methods were used to determine relative skin pigmenta-
tion. Initially, skin types were assessed based on standard skin typing
which uses skin/eye color, race and subjective recall of their re-
sponses to sun exposure for classification (19,20). Once recruited
each subject was tested to determine the erythemal dose response
using a template with eight 1.5 cm2 squares adhered to the left but-
tock. (All other areas were draped.) The dose of exposure to each
square on the grid was controlled by exposure time. Fair-skinned
subjects were exposed at 30 s intervals from 0.5 to 4 min (60 mJ/
cm2). Dark-skin subjects were exposed at 1 min intervals from 1 to
8 min (120 mJ/cm2). Very dark-skinned individuals were exposed
at 1 min intervals for 3–10 min (150 mJ/cm2). Erythema was as-
sessed 24 h after exposure. The first square with even, visible ery-
thema to the borders of the square was used to establish the minimal
erythemal dose (MED). In addition to this relatively subjective as-
sessment the erythemal dose response was determined more objec-
tively using a Chroma Meter CR-300 (Minolta Corp, Ramsey, NJ)
which converts all colors within the range of human perception into
a common numerical code. Degree of redness is indicated by ‘‘a’’,
where a 5 60 indicates red and a 5 260 indicates green. ‘‘L’’
indicates the degree of lightness, where L 5 0 indicates black and
L 5 100 indicates white. Chroma meter readings were obtained for
each of the eight exposure sites on the grid and the redness value
was plotted against the dose of UV delivered. Each subject was
assigned a number that reflected the slope of this erythemal dose
response curve (sED). Subjects with a D in redness $2 at two suc-
cessive UV doses were assigned an sED of 1; if the slope was
moderate (D in redness at two successive UV doses 0.5–2.0), the
sED assigned was 2; if the slope was flat (D in redness at two
successive UV doses ,0.5), the sED assigned was 3. Examples of
sED 1 and sED 2 are shown in Fig. 1. sED 3 was essentially a flat
line. The chroma meter was also used to assess baseline pigmenta-
tion (buttock skin prior to UVR) and the pigmentary response to
UV after 1 week.
Study population. The initial study population included 129 sub-
jects. Tables 2 and 3 provide demographic information on these
subjects. Subjects were group by skin type (Table 2) based on pho-
tosensitivity as determined by MED. This cohort contained only 20
individuals with MED of 30–37.5 mJ/cm2. In order to increase the
number of fair-skinned individuals in the study, data from an addi-
tional group of 56 subjects (33 males and 23 females) obtained in
another nonconcurrent, but similarly randomized, study were in-
cluded in some of the data analyses. Most of the UV-exposed sub-
jects in this study had MED between 30 and 37.5 mJ/cm2; six (three
males and three females) had MED below this range (24–27 mJ/
cm2) and one male and one female had MED above this range (45–
60 mJ/cm2).
UV exposure and chemical sensitization. Two to four weeks after
MED testing, individuals within a given skin type (defined by MED)
were prospectively randomized, stratifying for gender and assigned
to a UV or control exposure group. UV exposures were 1.5, 2.5 or
4 MED. (From this point on exposure doses will be expressed in
mJ/cm2.) Because MED could not be readily determined for subjects
with MED .100, randomly assigned fixed doses of UV were ad-
ministered to this group (120, 180 and 400 mJ/cm2). A single UV
dose was administered to a 3 3 4 in. site on the left buttock. (All
other areas were draped). Chroma meter readings were also done at
2 weeks to assess the tanning response for the various skin types.
Subjects were sensitized with 0.062% dinitrochlorobenzene (DNCB)
on the left buttock and 0.048% diphenylcyclopropenone (DPCP)
(Aldrich Chemical Co., Inc., Milwaukee, WI) on the right buttock
72 h following the UV exposure as previously described (11). Con-
trol subjects were similarly sensitized. Female subjects were sensi-
tized 7–21 days after the last menstrual period because sensitization
during the 1–6 day time frame gave less than optimal DNCB im-
munizations in the control group (21).
Challenge and scoring of elicitation response. Two weeks after
sensitization subjects were antigen challenged on unirradiated upper
inner arms as previously described (11). Five Finn chambers con-
taining acetone as a control or 3.125, 6.25, 8.8 or 12.5 mg DNCB
were applied to the right arm and four chambers containing 0.390,
0.781, 1.56 or 3.125 mg DPCP were applied to the left arm. The
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Figure 1. Examples of the erythemal dose response with a steep
slope (sED 1) and with a moderate slope (sED 2). The erythemal
dose response was assessed using a Minolta Chroma Meter CR-300,
where ‘‘a’’ indicates color on an axis from green to red (60 5 very
red, 260 5 very green). sED 1 5 D in redness at two successive
UV doses $2.0, sED 2 5 D in redness at two successive UV doses
0.5–2.0.
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*Minimal erythemal dose (the minimal dose required to produce skin reddening) range; MED refers here to the subject’s erythemal response
and is not a reference to the dose of UVR administered in the immune suppression studies.
†Chroma meter darkness–lightness scale (100 2 ‘‘L’’); mean 6 SE.
‡Increase in redness by chroma meter 24 h after 60 mJ/cm2, mean 6 SE.
§Based on slope of curve obtained from chroma meter readings of erythema at increasing doses of UVR (1 5 steep; 2 5 moderate; 3 5
flat); values are mean 6 SE.
\Roman numerals represent Fitzpatrick skin types contained within this group.
chambers were left in place for 6 h. An increase in skin fold thick-
ness at the site of challenge was determined using a micrometer
with spring-loaded calipers (Mitutoyo Manufacturing, Tokoyo, Ja-
pan), by subtracting the measurement before from the measurement
48 h after the chemical application. A single value which estimates
the integral for the entire dose response was recorded as the sum of
the increased skin fold thickness at the four DNCB or DPCP chal-
lenge sites (S edema at four sites).
Statistics. The initial analysis was done using data from 129 sub-
jects summarized in Tables 2 and 3. The data were made more
symmetric at each dose level, the variability was made more ho-
mogeneous and the response curve was straightened out by log-
transformation. Thus a linear dose model could be assumed for the
logarithm of the DNCB response. By including additional variables
in the model that significantly reduced the variability around the
regression line, the estimate of the dose coefficient was improved.
To test whether including a given variable would significantly im-
prove the model, a stepwise procedure was used on the following
main effects: age, sex (coded zero for females, one for males), MED,
baseline pigmentation, logarithm of the DPCP response, sensitiza-
tion batch number, time and time of year. After the significant main
effects were found their interactions and higher powers were also
tested (22).
In addition to the above variables there were two grouping vari-
ables of interest: the Fitzpatrick skin type groups and the groups
determined by the sED. The significance of each grouping was tested
separately using the regression model found above. In each case,
indicator variables were used to start with a full model that allowed
different coefficient values for each group. In the case of the sED
grouping the model was used to test which of the sED groups could
be combined as a single group without detracting from the model.
In the case of the Fitzpatrick grouping the model was examined to
see which variables in the original model were not affected by the
skin type grouping. Since only one subject was typed as a Fitzpatrick
type I, that subject was dropped for this part of the analysis and
only the five types, II–VI, were considered.
Finally, the combination of the supplemental study of 56 subjects
with the original study group of 129 subjects was considered. Since
several of the variables tested for inclusion in the model were not
available for this supplemental study, an abbreviated model was
used for the combined group to test the significance of the sED
grouping.
The relation between the DPCP response and the UVR dose was
also examined. The same models of main effects found for the
ln(DNCB response) were reanalyzed by switching the ln(DPCP re-
sponse) and ln(DNCB response) terms, thus examining the ln(DPCP
response) as a function of UVR dose.
RESULTS
Erythemal responses
Initially subjects were divided into five skin types based on
their MED response (Table 2). When these groups were ex-
posed to a fixed dose of 60 mJ/cm2, there was a progressive
decrease in erythema (assessed by chroma meter) as the
MED range increased (Table 2). There was a progressive
decrease in the sED with increased MED range, such that
for the group with the highest MED range it was difficult to
determine an MED. There was also a progressive increase
in baseline pigmentation. When subjects were grouped ac-
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*Based on slope of curve obtained from chroma meter readings of erythema at increasing doses of UVR (1 5 steep; 2 5 moderate; 3 5
flat); values are mean 6 SE.
†Chroma meter darkness–lightness scale (100 2 ‘‘L’’); mean 6 SE.
‡Increase in redness by chroma meter 24 h after 60 mJ/cm2, mean 6 SE.
§Mean and standard error of subjects MED responses.
\Roman numerals represent Fitzpatrick skin types contained within this group.
Figure 2. Scatter plot of immune response vs dose of UVB for 129
subjects initially studied. a: The data expressed as difference in skin
thickness. b: ln transformation of the data. R2 5 0.737. Coefficient
of dose is significant (P 5 0.002).
cording to sED (Table 3) progressive increases in these pa-
rameters and in the mean MED response were also observed.
Immune suppression dose response based on 129
subjects
The numbers of subjects in each MED group were not well
balanced and the number of subjects per group was relatively
low. Rather than arbitrarily combining groups to overcome
these problems, we began our analysis by considering the
entire data set. Figure 2a plots the immune response to
DNCB against the dose (mJ/cm2) of UV and shows that the
response diminishes with increasing dose, but the effect
seems to level off from 300 to 400 mJ/cm2, i.e. the response
is not linear. Also, the data are more spread out where the
response is high (for low UVR doses) than where the re-
sponse is smaller (for high doses), and the data are skewed
on the low side because there are more low responders than
high responders at every dose level. Hence, the distributions
are asymmetric. These problems are greatly reduced in Fig.
2b, which plots the logarithm of the immune response
against the dose of UVR. Although the slope of the line in
Fig. 2b is quite shallow, when the logarithm of the DNCB
response was regressed against the UVR dose without any
additional covariates, the dose response was seen to be high-
ly significant (P 5 0.002) but explained only a small part of
the variability in the data (R2 5 0.0737), i.e. only 7.37% of
the variability in the data is explained by the UVR dose.
Several experimental variables (main effects) were found to
explain a significant (P , 0.05) amount of the variability in
the response to DNCB. These included the sex, age, batch
number for the DNCB solution used to sensitize the subjects,
the response to DPCP and of course dose. Surprisingly nei-
ther of the variables associated with pigmentation (MED or
baseline pigmentation) was selected by the stepwise process
for inclusion in the regression model, indicating that differ-
ences in pigmentation did not significantly affect the re-
sponse to UVR-induced immune suppression. The analysis
of the two grouping variables, sED and the Fitzpatrick skin
type classification, also suggested that pigmentation did not
have a significant effect on the UVR dose response for im-
mune suppression.
Expanding the dose response to include 185 subjects
Since the original study population did not include many
very fair subjects, supplemental data from 56 fair-skinned
subjects assessed in a similar study were added to the data
from the study described above. Again, most of the variables
associated with pigmentation did not contribute significantly
to the variability in the DNCB response. However, in con-
trast to the earlier analysis, the model that included the 56
fairer subjects (all with sED 5 1) was significantly improved
by adding the sED grouping. Combinations of the groups
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Figure 3. The dose response model using sED as a grouping vari-
able and including 185 subjects from the combined studies. For sub-
jects with sED 1 (circles and solid line) 50% suppression of the
response 5 114 mJ/cm2. Confidence interval (95%) is 69 and 170
mJ/cm2. For subjects with sED 2/3 (squares and broken line) the
50% suppression dose could not be computed because the dose re-
sponse was too shallow.
Figure 4. Distribution of subjects in the sED 1 (solid bars) and
subjects in the sED 2/3 groups (hatched bars) with respect to MED.
Data are from combined studies (185 subjects).
were tested to see if any two of the groups could be com-
bined. No difference was found between the groups with
sED 2 and 3, but this combined group was significantly dif-
ferent from the group with sED 1. The dose responses for
subjects with sED 1 and sED 2/3 subjects combined are
shown in Fig. 3. The lack of a dose response for the sED 2/
3 group is obvious. Because the dose coefficient for the com-
bined group with sED 2 or 3 was not significant, a mean-
ingful 50% immune suppression dose could not be found.
In order to compute the 50% immune suppression doses for
the subjects with sED 5 1, the following model was used:
ln(DNCB) 5 0.3181 1 0.2856 ln(DPCP) 2 0.7649
3 sex 1 0.0193 3 age 2 0.006102 3 dose
where DNCB and DPCP refer to the immune (contact sen-
sitivity) response to each chemical, dose was expressed as
mJ/cm2 and sex was expressed as zero for females and one
for males. All the variables associated with the model are
significant (P , 0.05). The dose of UVR required to sup-
press the immune response by 50%, derived from this equa-
tion, was 113.6 mJ/cm2 with a 95% confidence interval
(68.7, 170.3).
Figure 4 shows the distribution of subjects in the sED 1
and sED 2/3 groups with respect to MED and demonstrates
that the sED groups cannot be readily described by an MED
range. There is considerable overlap with some of the sED
2/3 subjects having lower MED and some of the sED 1
subjects having higher MED. It should also be noted that
sED groups cannot be readily described by Fitzpatrick skin
types contained within each group. Forty subjects in the Fitz-
patrick IV classification and six in the Fitzpatrick V classi-
fication were in the sED 1 group which also contained all
the Fitzpatrick I–III subjects. There were six Fitzpatrick IV
subjects in the sED 2/3 group which contained all the Fitz-
patrick VI subjects and all but six of the Fitzpatrick V sub-
jects.
No distant effect of UVR on immunization to DPCP
The response to DPCP, the antigen applied to unirradiated
skin, was not at all correlated with UVR dose. No significant
relationship between DPCP response and UVR dose could
be established.
DISCUSSION
The results of this study suggest that pigmentation does not
play a major role in the susceptibility to UVR-induced im-
mune suppression in humans. Neither baseline pigmentation
nor MED or Fitzpatrick classifications contribute signifi-
cantly to the dose response. Other investigators have also
suggested that melanin does not protect against UVR-in-
duced immune suppression (12). Because the contribution of
pigmentation to UVR-induced immune suppression is not
great and, as with most human studies, there is a great deal
of variability in the response to both UVR and DNCB, dose
responses for multiple skin types could not be developed.
This is at least, in part, due to the presence of UVR resistant
(sED 2/3) subjects across many skin type groups.
In contrast to pigmentation differences in sensitivity could
be distinguished between subjects with a steep erythemal
dose response curve (sED 1) and those with a moderate or
flat erythemal dose response curve (sED 2/3). We suggest
that the subjects with sED 2 or 3 were resistant to UVR-
induced immune suppression. This group included all of the
very dark-skinned subjects for whom an MED response
could not be readily calculated; hence, exposure concentra-
tions were not based on MED. Perhaps much higher expo-
sures would have produced both erythemal and immune-sup-
pression dose response curves. In any case this group is
clearly much more resistant than the sED 1 group. Although
the sED 2/3 group included all of the subjects with MED
responses greater than 90 mJ/cm2, it also included individ-
uals with MED responses as low as 45 mJ/cm2 and was not
limited to the most darkly pigmented subjects. Conversely,
our sED 1 group included many IV and some V skin types.
The results of this study suggest that the sED provides better
information on relative immune responsiveness than the
MED representing one point on the erythemal dose response
curve. However, the sED was determined using a chroma
meter whereas the MED was determined visually. Hence
some of the differences between use of MED and sED may
simply reflect differences in the methods used to assess er-
ythema.
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The finding that sED identifies the subgroup of human
subjects who are immune suppressed by UVB is novel.
These results are somewhat in contrast to recent studies in
mice which suggest that the molecular mechanisms under-
lying sunburn and immune suppression are different (23).
However, as in our study, Kelly et al. (13) also demonstrated
differences in erythemal dose rate for subjects exposed to
solar simulated radiation (SSR). Their studies showed that
for every 1 J/cm2 the erythemal response of skin types I/II
was significantly greater than for skin types III/IV. Unlike
our study their study was limited to Caucasians and their
skin type I/II subjects were more sensitive to SSR-induced
immune suppression than skin types III/IV. The Kelly study
used different methods than we did to assess MED and con-
tact hypersensitivity (CHS) and to analyze the data. They
also used a solar simulator rather than the FS-20. Any or all
of these differences in the two studies could account for the
differences in the results.
Covariates accounted for about 50% of the variability in
the data presented here. Genetic differences in susceptibility
may account for a portion of the remaining variability al-
though other factors such as nutritional status might also be
involved (24–26). In mice susceptibility to UVR-induced
immune suppression appears to be dictated by alleles at
polymorphic loci that regulate the production of proinflam-
matory cytokines (27). Yoshikawa et al. (10) demonstrated
that 60% of normal healthy volunteers were resistant to
UVR-induced suppression of contact sensitivity using a pro-
tocol similar to that employed in this study. Our sED 2/3
group represents only 30% of the total number of subjects.
We used a much lower dose of DNCB (30 mg) than that
used in the Yoshikawa study (2000 mg). Mouse studies sug-
gest that immunosuppression is likely to be more readily
observed with a lower dose of antigen (28). Rather than two
distinct populations of UVR resistant and susceptible popu-
lations, there may be a more graded response such that the
greater the antigenic stimulus, the higher the number of re-
sistant subjects. The potential for greater sensitivity to UVR
using a lower dose of antigen is desirable when the goal is
to establish a dose response curve to be used in risk assess-
ment. Unfortunately, using a lower concentration of DNCB
increases the number of subjects with a very low response
to DNCB. This complicated the data analysis. If a large
number of subjects were present in the study population that
was simply unresponsive to DNCB, our analysis would have
underestimated the effect of UVR on the responsive group.
However, at higher doses 97.2% of subjects tested responded
to DNCB (10), suggesting that the number of truly unre-
sponsive subjects is likely to be low.
There was no evidence of systemic or distant immune
suppression comparable to that seen in mice (29). Suppres-
sion of the DPCP response (following sensitization at a site
distant from the site of radiation) was not observed. Other
investigators failed to detect local UVR-induced immune
suppression following sensitization with DPCP at the site of
radiation (30), suggesting that DPCP may not be the ideal
sensitizer. Others have demonstrated suppression of the sys-
temic response using DNCB (31). The mechanisms associ-
ated with systemic suppression in mice (29) appear to exist
in humans as well (32–34). Because there is some evidence
that the mechanisms responsible for UVR suppression of the
delayed-type hypersensitivity response and UVR suppres-
sion of contact sensitivity at a distant site are not identical
(35), it might be best to pursue further study of systemic
effects in humans using a microbial antigen, given that a
primary concern associated with systemic suppression is en-
hanced susceptibility to infectious disease.
The dose responses in this paper are valuable for risk as-
sessment because they are based on physical units (similar
to those used in exposure assessments) rather than biological
units (MED). In order to understand the impact of depletion
of stratospheric ozone on immune responses, risk assessors
ideally need action spectrum data on the immunosuppressive
effects of UVB at wavelengths most likely to be affected by
ozone depletion (295–305 nm) (36). Neither data obtained
with an FS-20 sun lamp nor data obtained with a solar sim-
ulator (13) provides this information. In a mouse study only
about 64% of the immunosuppressive activity of the FS lamp
was attributed to these wavelengths (37). The remaining im-
munosuppressive activity is attributed to wavelengths below
295 which are unlikely to be affected by currently predicted
ozone depletion. Also, we have demonstrated immune sup-
pression in humans exposed to higher UVA-II wavelengths
(38). Hence, the predictions in this study may be too con-
servative. For risk assessment purposes it may be reasonable
to make mathematical adjustments based on the action spec-
trum in mice. A dose response generated with a solar sim-
ulator (295–400nm) (13) poses a different problem in that
much of the J/cm2 are generated by wave lengths that are
neither immunosuppressive nor affected by ozone. Although
such data are useful for predicting risks associated with cur-
rent solar exposure, exactly how to adjust this dose to predict
effects of small increases in mJ/cm2 at the most immuno-
suppressive end of the spectrum is unclear.
The only other report of dose response data in humans
using an FS lamp indicated that the mixed skin lymphocyte
response (MSLR) was suppressed by 50% at a dose of 420
mJ/cm2 (39). This number is certainly higher than that of
114 mJ/cm2 obtained for the sED 1 group in our study, but
confidence intervals for the MSLR data were not shown.
Therefore, it is unclear how different the two numbers really
are. Clearly, the MSLR is a different endpoint although it is
presumably related to the contact sensitivity response as-
sessed in our study. The 50% suppression point computed
using our data compares favorably with that reported by
Noonan and coworkers (40,41) for systemic and local sup-
pression of contact sensitivity in highly sensitive strains of
mice (ranging from 70 to 230 mJ/cm2). It also compares
favorable with data reported by Jeevan and Kripke (6) for
suppression of the delayed-type hypersensitivity response to
mycobacterium bovis bacillus Calmette-Guerin (BCG) (270
mJ/cm2) in more resistant BALB/c mice and with values
reported for suppression of local contact sensitivity respons-
es in C3H/HeNCr mice, but it is lower than that reported to
suppress DTH and systemic CHS responses in the same
study (35). All of the above studies were conducted using
FS lamps. More recently Kelly et al. (13) provided human
erythemal and immune suppression dose response data using
a solar simulator. Because much of the energy in their source
came from higher wavelengths direct comparison between
our study and theirs is difficult. The dose computed to sup-
press the local contact sensitivity response in our sED 1
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subjects is environmentally relevant; 114 mJ/cm2 could be
encountered upon exposure to 1–2 h of midday summer sun
in the central US. Such exposures could have an impact on
the effectiveness of vaccines administered through the skin
and susceptibility to arthropod borne infections. These latter
possibilities deserve further study.
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